April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

Active Surveillance vs Standard Surgery After Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survi...

The ASCO Post

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Parker Institute for Cancer Immunotherapy Names New CEO

The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO).

The ASCO Post

March 28, 2025

New Dosing Option for Hemophilia A and B

The FDA approved Qfitlia (fitusiran) for hemophilia A or B prophylaxis in patients aged 12 and older, offering reduced bleeding rates with bi-monthly dosing.

Conexiant

March 27, 2025

Tampon Test May Detect Endometrial Cancer

New research from the Mayo Clinic shows promising results for a noninvasive methylated DNA marker panel that could reduce the number of unnecessary and painful biopsies in patients with abnormal uterine bleeding.

Conexiant

March 26, 2025

HER2-Selective TKI in Advanced Solid Tumors with HER2 Alterations

In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors....

The ASCO Post

March 26, 2025

State Eyes New Tools to Bolster Health Workforce

Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.

KFF Health News